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Abstract
Background
Several intracellular Leishmania antigens have been identified in order to find a potential
vaccine capable of conferring long lasting protection against Leishmania infection. Histones
and Acid Ribosomal proteins are already known to induce an effective immune response
and have successfully been tested in the cutaneous leishmaniasis mouse model. Here, we
investigate the protective ability of L. infantum nucleosomal histones (HIS) and ribosomal
acidic protein P0 (LiP0) against L. infantum infection in the hamster model of visceral leish-
maniasis using two different strategies: homologous (plasmid DNA only) or heterologous
immunization (plasmid DNA plus recombinant protein and adjuvant).
Methodology/Principal Findings
Immunization with both antigens using the heterologous strategy presented a high antibody
production level while the homologous strategy immunized group showed predominantly a
cellular immune response with parasite load reduction. The pcDNA-LiP0 immunized group
showed increased expression ratio of IFN-γ/IL-10 and IFN-γ/TGF-β in the lymph nodes be-
fore challenge. Two months after infection hamsters immunized with the empty plasmid pre-
sented a pro-inflammatory immune response in the early stages of infection with increased
expression ratio of IFN-γ/IL-10 and IFN-γ/TGF-β, whereas hamsters immunized with
pcDNA-HIS presented an increase only in the ratio IFN-γ/ TGF-β. On the other hand, ham-
sters immunized with LiP0 did not present any increase in the IFN-γ/TGF-β and IFN-γ/IL-10
ratio independently of the immunization strategy used. Conversely, five months after in-
fection, hamsters immunized with HIS maintained a pro-inflammatory immune response
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(ratio IFN-γ/ IL-10) while pcDNA-LiP0 immunized hamsters continued showing a balanced
cytokine profile of pro and anti-inflammatory cytokines. Moreover we observed a significant
reduction in parasite load in the spleen, liver and lymph node in this group compared
with controls.
Conclusions/Significance
Our results suggest that vaccination with L. infantum LiP0 antigen administered in a DNA
formulation could be considered a potential component in a vaccine formulation against
visceral leishmaniasis.
Author Summary
Visceral leishmaniasis caused by Leishmania infantum is the most severe form of leish-
maniasis. The disease is fatal if not treated and there is no vaccine available for human use.
In the search for potential antigens, the protective ability of conserved parasite protein
families such as L. infantum histones (HIS) and acidic ribosomal (LiP0) antigens were suc-
cessfully tested in the mouse model of cutaneous leishmaniasis. Here, we evaluate HIS and
LiP0 antigens using two different immunization strategies in the hamster model of visceral
leishmaniasis. Hamsters are highly susceptible to L. infantum infection and we demon-
strate that immunization with LiP0, but not HIS, protects against the fatal outcome of vis-
ceral leishmaniasis. Immunization with LiP0 was able to induce an increased expression
of IFN-γ in detriment of IL-10 and TGF-β in the draining lymph node before infection
creating an inhospitable environment for parasite growth. Following challenge, a reduced
parasite load in the lymph node, spleen and liver of LiP0 immunized hamsters was
detected five months after challenge. These findings suggest that LiP0 used in a DNA for-
mulation could be considered a potential component in a vaccine formulation against
visceral leishmaniasis.
Introduction
Leishmaniasis is a parasitic disease caused by protozoan from the genus Leishmania transmit-
ted by the bite of infected sand flies. Leishmaniasis is one of the six major tropical diseases tar-
geted by the World Health Organization [1]. The disease has a broad spectrum of clinical
manifestations, from cutaneous, self-limited skin lesions to a visceral form of the disease. Vis-
ceral leishmaniasis (VL) caused by Leishmania infantum in the NewWorld is the most severe
form of disease characterized by hepatosplenomegaly, fever with a high mortality rate if not
treated [2].
Although extensive research has been performed to identify an antigen able to elicit a long
lasting protection against infection, there is still no successful vaccine available for human
leishmaniasis. The majority of Leishmania vaccine candidates tested are able to induce humor-
al and/or cellular immune responses. However, the immune response derived is not able to in-
duce protection and may contribute to pathology exacerbation [1].
Several secreted and surface Leishmania antigens have been tested, targeting virulence fac-
tors or molecules important for parasite invasion but most of these candidates resulted in a
short-lived or partial protection [3]. On the other hand, intracellular house-keeping proteins
are able to modulate the host immune response because they do not undergo selective pressure
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by the immune response [4]. During infection, these molecules are released after the destruc-
tion of intracellular amastigotes by activated macrophages but they can be also excreted by
non-classical secretion pathways [5,6]. Several intracellular antigens such as heat shock pro-
teins, ribosomal proteins and histones have been investigated as potential vaccine candidates
against different species of Leishmania [3]. Histones (HIS) are important structural proteins in
the organization and regulation of genes. There are four main classes of histones (H2A, H2B,
H3, and H4) that are responsible for the composition of the Leishmania nucleosome [7]. Iborra
et al demonstrated that immunization with DNA plasmid coding for nucleosomal histones
plus CpG adjuvant was able to significantly reduce lesion size after challenge with L.major in
BALB/c mice [8]. More recently, Carneiro et al. observed that mice immunized with either a
plasmid DNA cocktail composed of four different Leishmania histones or with a combination
of the DNA cocktail followed by the corresponding recombinant proteins, resulted in the ab-
sence of infected macrophages at the site of challenge with L. braziliensis in the presence of
sand fly saliva. The protective response was associated with increased expression of IFN-γ and
down regulation of IL-4 at the infection site [9].
Another immunodominant antigen is the Leishmania infantum acidic ribosomal protein
(LiP0), a structural component of the large ribosome subunit that has been recognized by
sera from both patients and dogs infected by L. infantum [10,11]. Also, it has been demon-
strated that ribosomal protein (P0) was able to stimulate proliferation and IFN-γ secretion of
a T-cell clone established from a human donor by stimulation with paraformaldehyde fixed
promastigotes [12]. Using an immunization strategy that included LiP0 plasmid DNA vacci-
nation and/or with LiP0 recombinant protein plus CpG, Iborra et al. showed the induction of
partial protection against L.major infection in BALB/c mice [13]. However, C57BL/6 mice
immunized with the same strategy was able to significantly reduce parasite load controlling
lesion development [14]. The induction of IFN-γ was related with protection against Leish-
mania infection in these models. Although not demonstrated in Leishmania, it has been
shown that P0 can be located in the surface of some protozoan parasites from the genus
Plasmodium and Toxoplasma [15]. Its location on the cell surface of these organisms
underlies the protective responses elicited by different vaccines based on P0 antigen. Thus,
the generation of humoral responses to Neospora caninum P0 induces protection against
neosporosis and toxoplasmosis [16]. Similarly, an experimental vaccine based on the car-
boxy-terminal domain of Plasmodium falciparum P0 was able to induce humoral responses
that protects mice against malaria [17].
However, the immunization strategy used can be imperative to improve immunogenicity.
The heterologous prime-boost strategy is used combining different formulations of the same
antigen and has been effective in immunizations against cutaneous and visceral leishmania-
sis. Dogs immunized with LACK using the heterologous strategy (DNA/protein) presented
protection against VL caused by L. infantum [18]. Similarly, Iborra et al. (2005) used the
same strategy with pcDNA3-LiP0 followed by recombinant protein (rLiP0) that protected
C5BL/6 mice against challenge with L.major [14]. Moreover, administration of CpG ODN
with antigens from different pathogens has been shown to induce a strong Th1 immune re-
sponse [19].
Therefore, based on the protective potential of antigens belonging to conserved protein
families used in the cutaneous leishmaniasis mouse model, we hypothesized that immunization
with HIS and LiP0 antigens could also protect hamsters against the fatal outcome of L. infan-
tum infection. In addition, we also compared HIS and LiP0 antigens using two different
immunization strategies: plasmid DNA only (homologous) or plasmid DNA and recombinant
protein plus CpG ODN (heterologous).
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Methods
Animals
Male Syrian golden hamsters (Mesocricetus auratus) six to eight weeks old were obtained from
Centro de Pesquisa Gonçalo Moniz/ Fundação Oswaldo Cruz (FIOCRUZ) animal facility. All
animal work was conducted according to the Guidelines for Animal Experimentation of the
Colégio Brasileiro de Experimentação Animal and of the Conselho Nacional de Controle de
Experimentação Animal. The local Ethics Committee on Animal Care and Utilization (CEUA)
approved all procedures involving animals (CEUA—Centro de Pesquisas Gonçalo Muniz—
CPqGM/FIOCRUZ—L-IGM-011/09 and 005/2011.
DNA plasmids coding for LiP0 and nucleossomal histones
DNA plasmid coding for Leishmania infantum acid ribosomal protein (pcDNALiP0) and the
histones pcDNAHIS (pcDNA3LiH2-H3 and pcDNA3LiH2B-H4) were cloned and purified as
previously described [13,14].
Immunization strategies
Immunization experiments were carried out in groups of 15 hamsters. In the homologous im-
munization experiments, hamsters were inoculated three times intramuscularly (i.m.) with
100 μg of DNA of pcDNA3-LiP0, pcDNA3 HIS (50 μg of each plasmid) or pcDNA3 plus 1nM
of CpG ODN 1826 (18–24 pb—5´TCC ATGACG TTC CTG ACG TT-3´ mol wt 6364,1g/mol)
(empty plasmid) in a total volume of 50 μL. In the heterologous strategy, hamsters received
two inoculations of DNA followed by one intradermal (i.d.) inoculation of recombinant pro-
tein (5 μg of each rHIS or 10 μg rLiP0 protein) plus 1 nM of CpG ODN 1826 in the right ear
[20]. In all groups, hamsters were inoculated at 2-week intervals. Two weeks after the last im-
munization 15 hamsters per group were euthanized to collect draining lymph nodes and sera
to evaluate the cellular and humoral response induced by the immunization.
Determination of antibody titers
Fifteen days after last immunization and two and 5 months after infection a sample of blood
was collected from 6–8 hamsters per group by retrorbital plexus and sera was obtained after
centrifugation for 1500 rpm for 5 minutes and stored at -4°C until use. Briefly, to measure spe-
cific antibody responses by ELISA, standard ELISA plates were coated overnight at room tem-
perature with 100μL of SLA (10 μg/mL), rLiP0 (2μg/mL) or rHIS (1 μg/mL) in PBS. Serum
samples were added at dilutions of 1:100. Following a washing step, a goat anti-hamster IgG al-
kaline phosphatase conjugate (1:1,000 and 1:2,000, Sigma, Missouri, USA) was added and incu-
bated for one hour. The wells were then re-washed, substrate and chromogen (p-nitrophenyl
phosphate; Sigma, USA) were added, and absorbance was recorded at 405 nm on a SpectraMax
190 spectrophotometer (Molecular Devices, USA) automatic micro plate reader.
Intradermal challenge with Leishmania infantum
Leishmania infantum (MCAN/BR/00/BA262) promastigotes isolated from a naturally infected
dog (Bahia State, Brazil) were cultured in Schneider’s medium (LGC, Brazil) supplemented
with 10% of inactivated FBS (fetal bovine serum) (Gibco, USA), 2 mM L-glutamine, 100 IU/ml
penicillin, 1% streptomycin (Gibco, USA).
Fifteen days after the last immunization, hamsters were inoculated by intradermal route, in
the left ear with 105 stationary phase promastigotes plus 0.5 pair of sonicated salivary glands
(SGH) from female Lutzomyia longipalpis, using a 29-gauge needle (BD Ultra-Fine) in 20uL of
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saline. Salivary glands were dissected from 5- to 7-day-old females and stored in endotoxin-
free PBS at −70°C. Salivary glands were sonicated (Sonifer 450 homogenizer, Branson, Danbury,
Connecticut), and afterwards centrifuged at 12,000 g for 5 minutes. Supernatant was collected
and used immediately.
Limiting Dilution Assay (LDA)
Parasite load was determined 2 and 5 months post-infection using the quantitative Limiting
Dilution Assay (LDA) as described by Titus et al [21]. Briefly, infected liver, spleen and retro-
maxillar draining lymph nodes were aseptically removed from individual hamsters. Tissues
were homogenized and diluted in Schneider’s Insect Medium (Sigma, St. Louis, MO) supple-
mented with 10% heat inactivated fetal bovine serum (Gibco, USA), 100 U of penicillin/ml and
100 mg/ml of streptomycin. Homogenate samples were serially diluted into 96-wells plates
containing biphasic blood agar (Novy-Nicolle-McNeal) medium and incubated for one week
at 23°C when the presence of viable parasites was determined. Parasite burden in the tissue was
calculated applying ELIDA software [21].
RNA isolation and quantitative Real-Time PCR
Using Trizol reagent (Invitrogen, USA), total RNA was extracted from the draining retromaxillar
lymph nodes two weeks after the last immunization, and from the spleen obtained two and five
weeks after infection. First-strand cDNA synthesis was performed with 1–2 μg of RNA in a total
volume of 25 μL using Super Script II (Gibco, Carlsbad, CA, USA). DNA was amplified in the
thermocycler (Mastercycler gradient—Eppendorf, USA) with an initial pre- incubation at 72°C
for 5 minutes, followed by amplification of the target DNA at 42°C for 50 minutes. A standard
curve was generated for each set of primers and efficiency of each reaction was determined. The
expression levels of genes were normalized to GAPDH levels. Results are expressed in fold
change over control. Oligonucleotide primers used were: GAPDH (reverse 5’- CTGACATGC
CGCCCTGGAG-3’ and forward 3’-TCAGTG- TAGCCCAGGATGCC-5’); IFN-γ (reverse 5’-
GAAGCTCAC- CAAGATTCCGGTAA-3’ and forward 3’-TTTTCGTGACA- GGTGAGGCAT-
5’); IL-10 (reverse 5’-AGACGCCTTTCTC- TTGGAGCTTAT-3’ and forward 39-GGCAACTG
CAGCGC- TGTC-5’); and TGF-β (reverse 5’-GCTACCACGCCAACTTC- TGTC-3’ and for-
ward 3’-TGTTGGTAGAGGGCAAGG-5’).
Histology
For histology, five months after infection spleen and liver fragments of four hamsters from
each group were fixed in 10% phosphate-buffered formalin and embedded in paraffin. Four-
micrometer sections were stained with hematoxylin–eosin and studied by optical microscopy.
Statistical analysis
Experiments were repeated three times with five hamsters per group per time point. Compari-
sons among immunized and non-immunized control groups were done by one-way ANOVA
(Kruskal-Wallis) analysis with Dunn’s post-test. Results were considered statistically signifi-
cant when p0.05. All statistical analysis was done using Graph Pad 5.0 software program.
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Results
Heterologous immunization strategy using HIS or LiP0 antigens induces
production of specific antibodies
To evaluate production of anti-HIS or anti-LiP0 IgG antibodies we collected sera from immu-
nized hamsters fifteen days after the last immunization. We observed that only hamsters that
were immunized with heterologous strategy showed significantly higher titers of antibodies.
There was a significant increase of IgG in the group that received DNA plasmid coding for HIS
followed by booster of nucleosomal histone recombinant protein plus CpG adjuvant (pcDNA
HIS-rHIS+CpG) compared to non-immunized hamsters (Fig. 1A). Similar results were ob-
served regarding antibody production in hamsters immunized with LiP0, using the same heter-
ologous strategy. There was a significantly higher production of anti-LiP0 IgG in vaccinated
hamsters (pcDNA-LiP0/ rLiP0+CpG) compared to the animals that received empty plasmid
and saline, the control groups (Fig. 1B).
Immunization with DNA plasmid coding HIS and LiP0 proteins increase
expression of IFN-γ in the lymph node
In order to verify the cellular immune response induced by the immunization with HIS and
LiP0, expression of IFN-γ, IL-10, and TGF-β was evaluated in retromaxillar draining lymph
nodes 15 days after immunization. We observe a significant increase in the ratio of IFN-γ/IL-10
expression in the lymph nodes of animals immunized with HIS and LiP0 using the homolo-
gous immunization strategy with DNA plasmids (Fig. 2A). Conversely, there was no difference
in the IFN-γ/TGF-β ratio in the HIS immunized group using both immunization strategies
(Fig. 2B). Interestingly, we observed that the IFN-γ/TGF-β ratio was significantly higher in
hamsters immunized with DNA plasmid (pcDNA-LiP0) using homologous strategy compared
with the control group (Fig. 2B).
Fig 1. Humoral immune response after immunization with nucleosomal histones (HIS) or acidic ribosomal protein (LiP0) antigens.Hamsters
(n = 6–10) were bled 2 weeks after immunization and sera were tested by ELISA to determine specific total IgG levels. (A) Anti-HIS total IgG in sera from
hamsters immunized with recombinant DNA coding for HIS (pcDNA HIS) or with recombinant DNA followed by recombinant nucleosomal histones+CpG
(pcDNA HIS-rHIS+CpG). (B) Anti-LiP0 total IgG in sera from hamsters immunized with recombinant DNA coding for LiP0 (pcDNA LiP0) or with recombinant
DNA followed by recombinant protein LiP0+CpG (pcDNA LiP0- rLiP0+CpG). Control groups were immunized with saline or empty plasmid. *p<0.05;
**p<0.01; ***p<0.001, compared with controls.
doi:10.1371/journal.pntd.0003490.g001
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Immunization with LiP0 protects hamsters against the fatal outcome of
visceral leishmaniasis
In order to verify if the immune responses resulting from immunization with acidic ribosomal
protein and nucleosomal histone antigens using homologous and heterologous immunization
strategies, are able to protect against L. infantum infection, immunized hamsters were chal-
lenged with 105 L. infantum plus SGH, trying to mimic natural transmission [22].
Two months after challenge, hamsters immunized with HIS using the homologous strategy
showed a significant parasite load reduction in the liver (Fig. 3C) but not in the retromaxillar
lymph nodes or spleen compared to control groups (Fig. 3A and B).
On the other hand, we observed a significant reduction in the lymph node, spleen and liver
parasite loads in LiP0 DNA plasmid (pcDNA3-LiP0) immunized group, compared with con-
trols five months after challenge (Fig. 3A, B and C). Interestingly, parasite burden in the spleen
(Fig. 3B) (p = 0.0016) and liver (Fig. 3C) (p = 0.0001) of hamsters immunized with the LiP0-
based DNA vaccine were lower at 5 months than 2 months after infection, indicating that the
vaccine was able to induce a long term leishmanicidal response.
Antibody levels in HIS and LiP0 immunized hamsters after L. infantum
infection
To access the humoral immune response after infection, we measured production of anti-LiP0,
HIS and SLA IgG antibodies. For this purpose, we collected sera from infected hamsters at two
and five months following challenge with L. infantum plus SGS.
We observed an increase in anti-HIS IgG in all groups immunized with HIS especially at
five months after infection (Fig. 4A). Conversely, LiP0 immunized groups did not present any
significant levels of anti-LiP0 IgG levels two and five months following infection when com-
pared with controls (Fig. 4B).
Interestingly, animals immunized with LiP0 homologous strategy showed a significantly
lower anti-SLA IgG levels at five months after infection compared to HIS immunized and con-
trols groups (Fig. 4C).
Cytokines detection in HIS and LiP0 immunized hamsters after L.
infantum infection
To evaluate the cellular immune response of hamsters challenged with L. infantum, we investi-
gated the expression of cytokines in the spleen two and five months following infection.
Fig 2. Cytokine expression following immunization with nucleosomal histones (HIS) or acidic ribosomal protein (LiP0) antigens.Hamsters
(n = 6–10) were immunized with HIS or LiP0 antigens using the homologous (DNA only) or heterologous (DNA-recombinant protein plus CpG) and
retromaxillar lymph nodes collected for evaluation of cytokines expression by Real-Time PCR, two weeks after the last immunization. (A) IFN-γ/IL-10
mRNA expression ratio and (B) IFN-γ/TGF-βmRNA expression ratio. *p<0.05; **p<0.01; ***p<0.001, compared with controls.
doi:10.1371/journal.pntd.0003490.g002
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Two months after challenge hamsters immunized with DNA-HIS (homologous strategy)
presented an increased expression ratio of IFN-γ/IL-10 when compared with the non-immu-
nized control group (p = 0.0253) (Fig. 5A). Expression ratio of IFN-γ/TGF-β was increased in
the pcDNA-HIS (p = 0.0003), and pcDNA-HIS/rHIS+CpG (p = 0.018) immunized groups
compared with saline control suggesting that DNA-HIS immunized hamsters presented a pro-
inflammatory immune response in the early stages of infection (Fig. 5B). On the other hand,
hamsters immunized with LiP0 using independent of strategy employed did not present any
increase in the expression ratio of IFN-γ/IL-10 or IFN-γ/TGF-β (Fig. 5A and B).
Fig 3. Parasite load in hamsters immunized with HIS or LiP0 antigens following L. infantum infection.
Hamsters (n = 15) were immunized with HIS or LiP0 antigens using the homologous (DNA only) or
heterologous (DNA-recombinant protein plus CpG). Two weeks after the last immunization, hamsters were
challenged in the left ear with 105 L. infantum in the presence of Lu. longipalpis SGH. Draining retromaxillar
lymph node (A), Spleen (B) and Liver (C) parasite loads per total organ were determined two and five months
after challenge by limiting dilution assay (LDA). *p<0.05; **p<0.01; ***p<0.001, compared with controls.
doi:10.1371/journal.pntd.0003490.g003
Fig 4. Humoral immune response in HIS or LiP0 immunized hamsters following L. infantum infection. Hamsters (n = 15) were immunized with HIS or
LiP0 antigens using the homologous (DNA only) or heterologous (DNA-recombinant protein plus CpG). Two weeks after the last immunization, hamsters
were challenged in the left ear with 105 L. infantum in the presence of Lu. longipalpis SGH. Two and five months after challenge sera were tested by ELISA to
determine specific total IgG levels. (A) Anti-HIS total IgG in sera from hamsters immunized with pcDNA HIS or with pcDNA HIS-rHIS+CpG. (B) Anti-LiP0 total
IgG in sera from hamsters immunized with DNA LiP0 or DNA LiP0-rLiP0+CpG. (C) Anti-SLA total IgG in sera from hamsters immunized with HIS or LiP0.
*p<0.05; **p<0.01; ***p<0.001, compared with controls.
doi:10.1371/journal.pntd.0003490.g004
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Five months after infection, hamsters immunized with HIS using both immunization strate-
gies showed an increased expression ratio of IFN-γ/IL-10 (p<0.05) suggesting a pro-inflamma-
tory immune response (Fig. 5C). Concerning LiP0 immunization, there was an increase in the
expression ratio of IFN-γ/TGF-β in the spleen of pcDNA-LiP0/rLiP0+CpG immunized ham-
sters (heterologous strategy) compared with the control group (p<0.0101) (Fig. 5D) suggesting
that this strategy induce a delayed cellular immune response.
The spleen and liver of LiP0 immunized hamsters present fewer
granulomas and macrophage aggregates
Five months after infection spleen and liver samples were collected from four hamsters per
group for histopathological analysis. In the spleen, we observed disorganized follicles with or
without germinal center, macrophage aggregates with L. infantum amastigotes inclusions, epi-
thelioid cells present in the red and white pulp, as well as granulomas in the groups immunized
with HIS or LiP0. However, hamsters immunized with HIS displayed a higher loss of splenic
structure. . . Animals immunized with LiP0 presented smaller macrophage aggregates. Fig. 6
shows the granulomas present in the control (A) and LiP0 (B) immunized hamsters after infec-
tion (arrows).
At the same time point, liver from control and HIS immunized groups showed accentuated
intrasinusoidal leukocytosis with portal mononuclear infiltrate. Areas of necrosis and granulo-
mas containing giant cells filled with inclusions of amorphous material, few Schaumann bodies
Fig 5. Cytokine expression in the spleen of HIS or LiP0 immunized hamsters following L. infantum infection.Hamsters (n = 4–11) were immunized
with HIS or LiP0 antigens using the homologous (DNA only) or heterologous (DNA-recombinant protein plus CpG). Two weeks after the last immunization,
hamsters were challenged in the left ear with 105 L. infantum in the presence of Lu. longipalpis SGH. Spleen samples were collected for evaluation of mRNA
expression of IFN-γ, IL-10 and TGF-β by Real-Time PCR. IFN-γ/IL-10mRNA expression ratio at two (A) and five (C) months after challenge; and IFN-γ /TGF-β
mRNA expression ratio at two (B) and five (D) months after challenge. *p<0.05; **p<0.01; ***p<0.001, compared with controls.
doi:10.1371/journal.pntd.0003490.g005
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were observed (arrows in Fig. 6C). Although HIS and LiP0 immunized groups presented com-
parable intense inflammatory infiltrate the majority of hamsters immunized with LiP0 antigens
presented fewer granulomas (arrows in Fig 6D). These data were summarized in Table 1, show-
ing the number and percentage of animals displaying the histopathological alterations.
Discussion
Leishmania nucleosomal histones (HIS) and acidic ribosomal protein P0 (LiP0) elicit defined
immune responses and have been the focus of investigation as potential vaccines against cuta-
neous leishmaniasis [3]. Herein, we further explore their antigenic potential against the visceral
form of leishmaniasis. Using the susceptible hamster model of VL we show that both molecules
are immunogenic but only immunization with LiP0 is able to control disease progression.
Following immunization a notable difference was already observed on the profile of cyto-
kine expression in the draining lymph nodes. The expression ratio of IFN-γ/IL-10 of hamsters
Fig 6. Histological aspects of hamsters immunized with LiP0 antigen following L. infantum infection. Hamsters (n = 4) were immunized with HIS or
LiP0 antigens using the homologous (DNA only) or heterologous (DNA-recombinant protein plus CpG) immunization strategies. Two weeks after the last
immunization, hamsters were challenged in the left ear with 105 L. infantum in the presence of Lu. longipalpis SGS. Five months after challenge,
spleen (A and B) and liver (C and D) were obtained, from control (A and C) and LiP0 (B and D) immunized hamsters, fixed and stained with H&E for
histological evaluation.
doi:10.1371/journal.pntd.0003490.g006
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immunized with pcDNA-LiP0 and pcDNA-HIS was significantly higher compared with con-
trol groups. Interestingly, significant differences in the expression ratio of IFN-γ/TGF-β was
observed only in hamsters immunized with LiP0 using the homologous strategy. Similar results
were observed previously where production of IFN-γ but not IL-4 was detected in the spleen of
mice immunized with nucleosomal HIS antigens [8]. Another study also demonstrated IFN-γ
production upon stimulation of splenocytes and lymph node cells in vitro with rLiP0 after im-
munizations with pcDNA-LiP0 [13].
In the group immunized with empty vector we detected higher ratios of IFN-γ /IL-10 and
IFN-γ/TGF-β two months after infection, suggesting that the infection could be responsible for
this increase. Additionally, we did not detect the same levels for the control group (saline). The
empty vector contains CpG motifs that inespecifically increase production of inflammatory cy-
tokines, such as IFN-γ. It is important to emphasize that evaluation of cytokines in the spleen
was done ex vivo that does not comprise specific in vitro restimulation. Therefore, we can spec-
ulate that the higher number of parasites present in the spleen could contribute to the inflam-
matory pattern observed. However, IFN-γ expression was not sustained, five months after
infection cytokines ratios returned to basal levels that correlated with a high parasite load in
the liver and spleen. The same interpretation could be applied to the group immunized with
HIS, concerning the restimulation in vitro, where at two months, immunization with HIS in-
duce a lower IFN-γ/IL-10 ratio. However, five months after infection, the number of parasites
was high in the spleen and possibly, in an attempt to control parasite growth, there was an in-
crease in IFN-γ expression as observed in other reports in the literature [22]. Interestingly, the
ratio of IFN-γ/TGF-β presented opposite results, where we observed an increase in this ratio at
two months post-infection and a decrease five months after infection. We know that IL-10 and
TGF-β play similar roles in the inhibitory responses and we can speculate these cytokines
might alternate in the balance of pro and anti-inflammatory responses after infection [23,24].
Moreover, the expression ratio of IFN-γ/IL-10 and IFN-γ/TGF-β in the animals immunized
with LiP0 antigens did not present any significant increase, independently of the immunization
Table 1. Spleen and liver histopatholgical alteration after ﬁve months of infection in hamsters immunized with different strategies.
Spleen Folicles without germinal
center
Folicles with germinal
center
Follicles with atrophy Granuloma Macrophage
aggregates
Saline 1/4 (25%) 0/4 (0%) 2/4 (50%) 0/4 (0%) 0/4 (0%)
Empty Plasmid 1/4 (25%) 1/4 (25%) 0/4 (0%) 1/4 (25%) 0/4 (0%)
pcDNA-HIS 0/4 (0%) 2/4 (50%) 0/4 (0%) 2/4 (50%) 0/4 (0%)
pcDNA-HIS/rHIS
+CpG
0/4 (0%) 4/4 (100%) 0/4 (0%) 1/4 (25%) 1/4 (25%)
pcDNA-LiP0 0/4 (0%) 4/4 (100%) 0/4 (0%) 2/4 (50%) 0/4 (0%)
pcDNA-LiP0/rLiP0
+CpG
0/4 (0%) 3/4 (75%) 0/4 (0%) 3/4 (75%) 0/4 (0%)
Liver Leukocytosis Portal mononuclear
inﬁltrate
Inclusions of amorphous
material
Granuloma Macrophage
aggregates
Saline 2/4 (50%) 2/4 (50%) 0/4 (0%) 1/4 (25%) 1/4 (25%)
Empty Plasmid 3/4 (75%) 3/4 (75%) 0/4 (0%) 3/4 (75%) 0/4 (0%)
pcDNA-HIS 2/4 (50%) 0/4 (0%) 2/4 (50%) 2/4 (50%) 1/4 (25%)
pcDNA-HIS/rHIS
+CpG
3/4 (75%) 3/4 (75%) 0/4 (0%) 2/4 (50%) 0/4 (0%)
pcDNA-LiP0 2/4 (50%) 3/4 (75%) 0/4 (0%) 1/4 (25%) 0/4 (0%)
pcDNA-LiP0/rLiP0
+CpG
1/4 (25%) 3/4 (75%) 0/4 (0%) 1/4 (25%) 0/4 (0%)
doi:10.1371/journal.pntd.0003490.t001
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strategy used. Interestingly, these animals displayed a significant reduction in the parasite load
in lymph nodes, spleen and liver five months after infection, suggesting that this modulation in
the immune response is important for infection control. Hamsters immunized with LiP0 also
presented fewer infected granulomas and macrophage aggregates in the spleen and liver and
lower anti-SLA IgG levels after infection compared to the HIS immunized group indicating
control of parasite replication.
A significant production of IgG antibodies was also detected following immunization with
both antigens (LiP0 or HIS). Similarly, Iborra et al. also detected specific levels of IgG and
IgG2a in mice immunized with LiP0 and HIS antigens. Antibodies against a LiP0 ribosomal
protein epitope were also detected in dogs naturally infected with L. infantum [8,11,14]. Specif-
ic total IgG production was only detected when the heterologous immunization strategy was
employed. Indeed, vaccination strategies using exclusively DNA are known to elicit low IgG
production as previously demonstrated [25]. Interestingly, five months after infection, anti-
HIS and anti-LiP0 IgG levels increased in all groups with no significant differences between
immunization strategies.
The significant parasite load reduction observed in the pcDNA-LiP0 immunized group
after five months could be a result of the increased expression ratio of IFN-γ/IL-10 and
IFN-γ/TGF-β in the lymph nodes before challenge. The induction of a predominant Th1
immune response following immunization could have an impact on parasite establishment
and disease development. The importance of a Th1 environment established before challenge
was clearly demonstrated in hamsters immunized with LJM19, a vector salivary molecule,
Protection was associated with a considerably higher expression of IFN-γ/TGF-β ratio in the
spleen compared with controls [22].
Using the mouse model, Carrion et al. demonstrated that immunization with a pcDNA-HIS
vaccine and subsequently challenged with L. infantum did not result in parasite load reduction
[26]. Another study demonstrated different results with parasite load reduction in the spleen
and liver of mice immunized with HIS pulsed dendritic cells associated with CpG after L. infan-
tum infection. Protection was associated with a potent polarized Th1 type immune response
elicited by the immunostimulatory ability of HIS pulsed dendritic cells [27]. More recently, im-
munization with recombinant histones proteins from L. donovani was able to confer protection
against L. donovani infection [28].
In the cutaneous leishmaniasis model, the protective ability of HIS was demonstrated using
both homologous and heterologous immunization strategies. BALB/c mice immunized with
HIS, using both experimental approaches and challenged with L. braziliensis, were able to con-
trol lesion development, decreased parasite burden in lymph nodes and absence of infected
macrophages at site of infection [9]. In another study, DNA-HIS vaccines were able to reduce
the number of L.major parasites in the draining lymph node and spleen compared to controls
[8]. Contrasting results between different animal models and clinical forms were also observed
after immunization with KMP11, a different parasite antigen. Immunization of hamsters with
KMP11 was able to confer protection against L. donovani and L. infantum infection. The same
protective response was not observed when encapsulated KMP11 was used to immunize
BALB/c mice against L. braziliensis infection [29–31]. These contradictory findings concerning
visceral and cutaneous leishmaniasis models could be explained by the remarkable differences
in disease development and the host’s immune response depending on the animal model used.
Visceral leishmaniasis is a systemic chronic disease that affects many organs while cutaneous
leishmaniasis is characterized by a restricted skin lesion. Although the mouse model has been
extensively used to study cutaneous disease, infection with L. infantum is self-limiting. The
hamster model of VL is a well described model of susceptibility, with progressive disease that
more closely mimics the severity of infection in humans and dogs [32,33]. Assessment of long
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term memory is important when evaluating a potential vaccine candidate. Unfortunately, there
are no immunological tools available to investigate and characterize memory cells in hamsters.
Vaccines based on combination of different antigen candidates have been shown to improve
protection. In fact, a recombinant Q protein formed by genetic fusion of five parasite intracel-
lular antigens has been successfully tested in dogs [34–36]. Although this is imperative when
considering a new vaccine, the focus of this study was to initially test HIS and LiP0 antigens in-
dependently. Besides that, combination of vector salivary antigens, such as LJM19, and parasite
antigens could improve protection compared to immunization with isolated antigens. In order
to select the antigens that could be used in combination its necessary to initially evaluate their
immunogenicity and protection potential independently. Interestingly, more recent data pub-
lished by our group have showed that combination of LJM19 plasmid with KMP11, a parasite
antigen, was not able to improve protection resulting from immunization with LJM19 or
KMP11 alone in the hamster model[37].
There are two licensed vaccines for canine VL available in Brazil. The fucose mannose li-
gand of Leishmania donovani (Leishmune) [38,39] and the Leishmania amastigote recombi-
nant A2-antigen (Leish-Tec) [40]. In a recent study, no significant differences in the rate of
seroconversion, clinical signs, parasitism and parasite transmission to the vector were observed
in dogs vaccinated with any of the two vaccines [41]. Although both vaccines showed promis-
ing results, large-scale field studies are necessary to validate their inclusion in a mass control
strategy for canine VL.
Taken together, the data shown herein indicates that although L. infantum LiP0 and HIS an-
tigens were immunogenic in hamsters, only LiP0 antigen was able to confer a significant degree
of protection against L. infantum using the susceptible hamster model of VL. Importantly, we
also noted that the immunization strategy used is critical when a potential vaccine candidate is
being tested. Indeed, immunization with pcDNA-LiP0 followed by rLiP0 boost (heterologous
strategy) resulted only in short-term protection after two months. Our results suggest that L.
infantum LiP0 antigen administered in a DNA formulation (homologous strategy) is a poten-
tial vaccine candidate and further investigation of the protective mechanism could improve L.
infantum LiP0 protective effect against visceral leishmaniasis.
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